<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="110849">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01758965</url>
  </required_header>
  <id_info>
    <org_study_id>MD_SCHBC_IRB_2012-06</org_study_id>
    <nct_id>NCT01758965</nct_id>
  </id_info>
  <brief_title>Surgicel速 Fibrillar for Delayed Bleeding After ESD</brief_title>
  <official_title>Surgicel速 (Fibrillar) for Preventing Delayed Bleeding After ESD in Stomach: A Prospective Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soonchunhyang University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Soonchunhyang University Hospital</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the effect of Surgicel速 Fibrillar as adjuvant treatment
      to  H2RA on preventing ulcer bleeding after ESD for gastric epithelial tumors
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Patient (1) Inclusion: Diagnosed as gastric dysplasia or early gastric cancer

             -  Scheduled for ESD (2) Exclusion: Coagulopathy- liver cirrhosis, thrombocytopenia

             -  Anti-platelet agents

        2. Method

      (1) Study group: combination with Surgicel速 Fibrillar and H2RA (2) Control group:
      monotherapy with PPI 3. Sample size : 157 4. Result

        1. Primary endpoint: rate of delayed bleeding after ESD

        2. Secondary endpoint: follow-up hemoglobin after ESD
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Delayed bleeding rate after ESD</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">146</enrollment>
  <condition>Benign Neoplasm of Stomach</condition>
  <condition>Malignant Neoplasm of Stomach</condition>
  <arm_group>
    <arm_group_label>combination therapy of H2RA and surgicel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>H2RA and surgicel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monotherapy of PPI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PPI</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PPI</intervention_name>
    <description>monotherapy of PPI</description>
    <arm_group_label>Monotherapy of PPI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>H2RA and surgicel</intervention_name>
    <description>combination therapy of H2RA and surgicel</description>
    <arm_group_label>combination therapy of H2RA and surgicel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ESD for gastric dysplasia or early gastric cancer

        Exclusion Criteria:

          -  Coagulopathy: liver cirrhosis, thrombocytopenia

          -  Anti-platelet agents
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Digestive Disease Center, Department of Internal Medicine, Soonchunhyang University College of Medicine</name>
      <address>
        <city>Bucheon</city>
        <state>Gyeonggi-do</state>
        <zip>420-767</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 12, 2014</lastchanged_date>
  <firstreceived_date>December 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Soonchunhyang University Hospital</investigator_affiliation>
    <investigator_full_name>Su Jin Hong</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
